Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1738 • ACR Convergence 2025
Coexpression and Infiltration of Endoplasmic Reticulum Stress Proteins Together With CD34+ Fibroblast-like Synoviocytes In Human Inflamed Synovial Membranes
Zoe Gendebien¹, Pauline Salpetier², Celine Deroyer², Genevieve Paulissen², Alexandre Hego², Gaetan Lefevre², Christophe Poulet², Sophie Neuville², Patrick Durez³, Patrice Hemon⁴, Nadege Marec⁵, Elettra Bianchi², Philippe Delvenne², Clio ribbens² and Dominique de Seny², ¹ULiege, Liège, Belgium, ²ULiege, Liege, Belgium, ³Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Brussels Hoofdstedelijk Gewest, Belgium, ⁴Brest, Brest, Belgium, ⁵Brest, Brest, France
Background/Purpose: A strong crosstalk exists between endoplasmic reticulum (ER) stress and synovitis. Several ER chaperone proteins, besides their function in protein folding, can play a…
Abstract Number: 1659 • ACR Convergence 2025
Prevalence and Progression of Multimorbidity in Rheumatoid Arthritis-Associated Interstitial Lung Disease
James Fagerland¹, Yangyuna Yang¹, Punyasha Roul², Tate Johnson¹, Scott Matson³, Grant Cannon⁴, Brian Sauer⁵, Jeffrey Curtis⁶, Joshua Baker⁷, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, OMAHA, NE, ²UNMC, Omaha, NE, ³University of Kansas, Kansas City, MO, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Multimorbidity, the presence of multiple chronic conditions, is common in RA, and the progression of multimorbidity in RA is associated with poor long-term outcomes.…
Abstract Number: 1368 • ACR Convergence 2025
Thrombocytosis Predicts Response to Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis: Data from the Korean KOBIO Registry
Se Hee Kim¹ and kyung-Ann Lee², ¹Kyung Hee University College of Medicine, Seoul, Republic of Korea, ²Soonchunhyang University Hospital Seoul: Soonchunhyang University Hospital, Seoul, Republic of Korea
Background/Purpose: This study aimed to evaluate the clinical characteristics of thrombocytosis, its relationship with disease activity and joint involvement, and its influence on the effectiveness…
Abstract Number: 1350 • ACR Convergence 2025
Initial Biologic Therapy Improves Sexual Function in Female Patients with Rheumatoid Arthritis: A 6 Month Follow-Up Study
Daniel Zavada¹, Barbora Vala², Adela Navratilova², Veronika Losterova², Lenka Moravcova², Jiri Vencovsky³, Ladislav Šenolt⁴, Karel Pavelka⁵ and Michal Tomcik⁵, ¹Institute of Rheumatology, Prague; Charles University, Third Faculty of Medicine, Hlavné mesto Praha, Czech Republic, ²Institute of Rheumatology, Praha, Czech Republic, ³Institute of Rheumatology, Praha ⁸, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Rheumatoid arthritis (RA) significantly impacts quality of life in multiple domains. This study aimed to evaluate the impact of initial biologic/targeted synthetic disease-modifying anti-rheumatic…
Abstract Number: 1333 • ACR Convergence 2025
Assessment of lipid abnormalities after initiation of a JAK inhibitor in rheumatoid arthritis in clinical practice
Salomé Abdellaoui¹, Omar Al Tabaa¹, Sophie Hecquet¹, Alice Combier¹, Sandrine Carves¹, Olivier Fogel², Yannick Allanore³ and Jérôme Avouac⁴, ¹Rheumatology department, Cochin Hospital, Paris, France, ²AP-HP, Paris, France, ³Université Paris Cité, Paris, France, ⁴Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: rheumatoid arthritis (RA) is characterized by a lipid paradox induced by systemic inflammation. JAK inhibitors (JAKi) have been associated with a short-term increase in…
Abstract Number: 1317 • ACR Convergence 2025
The Association Between Insomnia and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 546,822 Patients
Mohamed Abdelsalam¹, Maryam Lasheen², Menat Alla Ayman Ali Mahdy³, Hadeer Hafez⁴, Nourhan Abouelella⁵, Mohamed Al-Adl⁶ and Mohamed Reda Awad⁷, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ³Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ⁴⁶th October University, ⁶ october, Al Jizah, Egypt, ⁵Faculty of Medicine, Misr University for Science and Technology, ⁶ october, Al Jizah, Egypt, ⁶Faculty of medicine Al-Azhar University Cairo, Nasr City, Egypt, ⁷Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt
Background/Purpose: Insomnia and rheumatoid arthritis (RA) are caught in a snowball effect, where chronic pain disrupts sleep and causes poor sleep quality, which in turn…
Abstract Number: 1239 • ACR Convergence 2025
JAK inhibition appears to alter clinical and neurobiological markers of nociplastic pain in rheumatoid arthritis: a 7T MRI Brain study
Kristian Stefanov¹, Andrew McGucken¹, Maxine Arnott¹, Tyrone Lau¹, Norah Aldehmi¹, Vinod Kumar², Neil McKay³, James Dale⁴, Lindsay Robertson⁵, James Brock¹, Flavia Sunzini⁶ and Neil Basu⁷, ¹University of Glasgow, Glasgow, United Kingdom, ²NHS Tayside, Dundee, United Kingdom, ³NHS Lothian, Edinburgh, United Kingdom, ⁴NHS Lanarkshire, Wishaw, United Kingdom, ⁵NHS Grampian, Aberdeen, United Kingdom, ⁶Glasgow University, Glasgow, United Kingdom, ⁷Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Pain remains a prevalent and highly impactful issue for people with rheumatoid arthritis (RA). Among modern day targeted therapies, the janus kinase (JAK) inhibitors…
Abstract Number: 1085 • ACR Convergence 2025
Bridging the Gap: The Use of Patient Joint Self-Assessment in RA Treatment Response Evaluation
Sri Lakshmi Sathiyaseelan¹, Sandeep Kansurkar², Kavita Krishna³ and Varsha Bhatt⁴, ¹Bharati Vidyapeeth medical college and hospital, chennai, Tamil Nadu, India, ²Bharti vidyapeeth (DTU) Medical College, Pune, Pune, Maharashtra, India, ³Bharati Vidyapeeth University Medical College and Hospital, Pune, Maharashtra, India, ⁴Department of Clinical Immunology and Rheumatology, Bharati Vidyapeeth (Deemed To Be) University Medical College,Pune, Pune, Maharashtra, India
Background/Purpose: Rheumatoid arthritis presents with multiple joint pains and it is traditionally, examined by the clinicians. The utility of patient self‐joint counts has become an…
Abstract Number: 1010 • ACR Convergence 2025
Confounding by Indication in Observational Studies Investigating Glucocorticoid-Associated Adverse Events in Patients with Rheumatoid Arthritis: A Systematic Literature Review
Andriko Palmowski¹, Anne Elisabeth Beenken², Anne Pankow², Judith Oldenkott², Henriette Käding², Edgar Wiebe³, Zhivana Boyadzhieva⁴, Eric L Matteson⁵, Ioanna Minopoulou⁶, Thorben Witte², David Simon⁷, Arnd Kleyer⁶ and FRANK BUTTGEREIT⁸, ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Charité, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁵Mayo Clinic College of Medicine and Science, Rochester, MN, ⁶Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ⁷Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ⁸Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Observational studies investigating glucocorticoids (GCs) and related adverse events (AEs) in patients with rheumatoid arthritis (RA) can suffer from bias by indication if confounders…
Abstract Number: 0914 • ACR Convergence 2025
Preclinical Expansion of Autoreactive Naive B cells Drives RA onset in ACPA+ individuals
Xiaohao Wu¹, Mengrui Zhang², Orr Sharpe³, V. Michael Holers⁴, Jane Buckner⁵, Gary Firestein⁵, Eddie James⁶, Kevin Deane⁷ and William H. Robinson⁸, ¹Stanford Uniersity, Stanford, ²Stanford University, Stanford, CA, ³Stanford University, Stanford, ⁴University of Colorado Anschutz Medical Campus, Aurora, ⁵Benaroya Research Institute, Seattle, ⁶Benaroya Research Institute, Benaroya Research Institute, ⁷University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁸Stanford University, Palo Alto, CA
Background/Purpose: The cellular and molecular mechanisms underlying the progression from anti-citrullinated protein antibody (ACPA) positivity to clinical rheumatoid arthritis (RA) remain poorly understood. Defining these…
Abstract Number: 0825 • ACR Convergence 2025
Rheum2Learn: A Randomized Trial of Virtual vs Text-Based Rheumatology Modules
Sonam Kiwalkar¹, Julianna Desmarais², Ellen Snyder³, Lisa Schroeder⁴, Marissa Meissner⁵, Noelle A. Rolle⁶, Sarah Donohue⁷, Brittany Bettendorf⁸, Ira Khanna⁹, Karen Kruzer¹⁰, Nkechi Emejuaiwe¹¹, Ibtissam Gad¹², David Leverenz¹³, Michael George¹⁴, Ashima Makol¹⁵, Floranne Ernste¹⁵ and Jilie Blaszczak¹⁶, ¹The Vancouver Clinic, Portland, OR, ²Oregon Health and Sciences University, Portland, OR, ³UNC Rheumatology, Chapel Hill, NC, ⁴Geisinger, Danville, PA, ⁵Geisinger Medical Center, Danville, PA, ⁶Medical College of Georgia at Augusta University, Evans, GA, ⁷University of Wisconsin, Madison, WI, ⁸University of Iowa, Iowa City, IA, ⁹Mount Sinai Hospital, New York, NY, ¹⁰Assistant Professor- University of Rochester, Victor, NY, ¹¹Cincinnati VA Medical Center, Cincinnati, OH, ¹²University of Michigan, Plymouth, MI, ¹³Duke University, Durham, NC, ¹⁴University of Pennsylvania, Philadelphia, PA, ¹⁵Mayo Clinic, Rochester, MN, ¹⁶University of Michigan, Ann Arbor, MI
Background/Purpose: Internal medicine (IM) residents often receive limited rheumatology training, contributing to low confidence in managing rheumatologic conditions and suboptimal performance on standardized examinations. Virtual…
Abstract Number: 0505 • ACR Convergence 2025
Use of Upadacitinib in Real-World Clinical Practice: Patient Characteristics and Glucocorticoid-Sparing Effect
Virginia Ruiz-Esquide¹, Lourdes Mateo², Carolina Pérez García³, Hye Sang-Park⁴, Susana Holgado⁵, María Aparicio⁶, Beatriz Frade⁷, Juan Camilo Sarmiento-Monroy⁸, Annika Nack⁹, Felipe Julio Ramirez Garcia¹⁰, José Gomez-Puerta¹¹ and Raimon Sanmartí¹, ¹Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ²Hospital Trías i Pujol, Barcelona, Catalonia, Spain, ³Hospital del Mar, Barcelona, Spain, ⁴Hospital Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ⁵Hospital Germans Trias i Pujol, Barcelona, Catalonia, Spain, ⁶Hospital Germans Trías i Pujol, Badalona, Catalonia, Spain, ⁷Hospotal Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁸Hospital Clínic Barcelona, Barcelona, Spain, ⁹Hospital Germans Trias i Pujol, Barcelona, Spain, ¹⁰Rheumatology Department, Hospital Clinic and IDIBAPS of Barcelona, Barcelona, Spain, ¹¹Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain
Background/Purpose: While clinical trials have demonstrated the efficacy of upadacitinib (UPA), real-world data are essential to understand patient characteristics and assess its effectiveness in routine…
Abstract Number: 0486 • ACR Convergence 2025
Safety of sarilumab in more than 1000 patients with rheumatoid arthritis in Japan by age group: a post-marketing surveillance study
Hideto Kameda¹, Sadatomo Tasaka², Toshiya Takahashi³, Naoki Soeda³, Katsuhisa Suzuki⁴ and Yoshiya Tanaka⁵, ¹Department of Internal Medicine, Toho University, Tokyo, Japan, ²Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan, ³Medical Affairs, Asahi Kasei Pharma Corporation, Tokyo, Japan, ⁴Medical Affairs, Sanofi K.K., Tokyo, Japan, ⁵University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: Sarilumab (SAR) is approved as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for treatment of patients (pts) with moderate-to-severely active…
Abstract Number: 0470 • ACR Convergence 2025
Characterization of Patients With Rheumatoid Arthritis Based on Distinct Patterns of Pain Improvement Following Treatment With Filgotinib: A Post Hoc Analysis of FINCH 1
Peter Taylor¹, Yoshiya Tanaka², Louis Dron³, Katrien Van Beneden⁴, Gerd Burmester⁵ and Bruno Fautrel⁶, ¹University of Oxford, Oxford, United Kingdom, ²University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³Cytel, Toronto, Canada, ⁴Alfasigma S.p.A., Bologna, Italy, ⁵Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁶Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France
Background/Purpose: Janus kinase inhibitors have been shown to ameliorate pain as well as inflammation in patients with rheumatoid arthritis (RA). Pain response trajectories were modeled…
Abstract Number: 0453 • ACR Convergence 2025
Safety of DMARDs in Rheumatoid Arthritis: A Nationwide Study of ILD Risk and Outcomes in RA-ILD
kyung-Ann Lee¹, Bora Lee², Hyun-Sook Kim³ and Se Hee Kim⁴, ¹Soonchunhyang University Hospital Seoul: Soonchunhyang University Hospital, Seoul, Republic of Korea, ²Chosun University, GwangJu, Republic of Korea, ³Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea, ⁴Kyung Hee University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a potentially life-threatening extra-articular manifestation of RA. The comparative safety of disease-modifying antirheumatic drugs (DMARDs) in RA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].